Rubella Diagnostic Testing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Rubella Diagnostic Testing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The major factors for the growth of the rubella diagnostic testing market include the government initiatives to curb the rubella virus, increasing incidences of rubella, and the introduction of advanced point-of-care diagnostic technologies, which are expected to boost the overall growth of the market over the forecast period.

There has been an increase in the number of incidences of rubella across the world. Rubella is an acute, contagious viral infection that causes a mild fever and rash illness in children and adults. Infection during pregnancy, especially during the first trimester, can result in miscarriage, stillbirth, fetal death, or infants with congenital malformations. According to the data published by the Centers for Disease Control and Prevention (CDC), rubella is a global health concern, and every year, more than 100,000 cases of congenital rubella syndrome (CRS) are reported, globally. A woman infected with rubella during the first three months of pregnancy has up to a 90% of chance of giving birth to a baby with congenital rubella syndrome.

On the other hand, as per the Global Vaccine Action Plan (GVAP) Assessment report, rubella control is lagging, with 42 countries yet to introduced the vaccine.

Key Market TrendsEnzyme Immunoassay Segment under Testing Technique Accounted for the Largest Share in the Global Market

• The detection of rubella-specific immunoglobulin M (IgM) in serum is the standard test for the rapid laboratory diagnosis of rubella.
• IgM testing is the most commonly performed testing technique using commercial enzyme immunoassay (EIA) kits. The blood test detects antibodies that are made by the immune system to kill the rubella virus, and these antibodies remain in the bloodstream for years.
• The segment is expected to account for the largest market share, owing to the rising incidences of rubella.

Asia-Pacific Accounted for the Highest Growth Rate in the Global Market

The Asia-Pacific segment, by geography, was found to register the fastest growth rate for the rubella diagnostic testing market, and is expected to show a similar trend over the forecast period, without significant fluctuations.

The Asia-Pacific region holds the highest market share, owing to the presence of larger untapped opportunities, a lack of awareness in some countries, and government initiatives to curb the disease incidence.

As per the Global Vaccine Action Plan (GVAP) Assessment report 2017, 42 countries have not yet introduced the vaccine, and two regions, Africa and the Eastern Mediterranean, have not yet set rubella elimination or control targets. Such regions are expected to face high incidences of rubella, which may further drive the growth of the market.

Competitive Landscape

The market studied is dominated by a few major players and most of the players present in the market are focusing on the development of new technologies to acquire the maximum market share. The presence of major market players, such as Abbott Laboratories, Bio Rad Laboratories Inc., BioMerieux SA, Siemens AG, and Thermo Fisher Scientific Inc., is increasing the overall competitive rivalry in the market.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Companies Mentioned

Abbott
Beckman Coulter Inc.
Bio Rad Laboratories Inc.
Biokit SA
bioMérieux SA
F. Hoffmann
La Roche Ltd
Ortho Clinical Diagnostics
Siemens Healthcare GmbH
Thermo Fisher Scientific
ZEUS Scientific Inc.

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.